Literature DB >> 3859743

Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem.

F Bessho, H Kinumaki, M Kobayashi, H Habu, K Nakamura, S Yokota, T Tsuruo, N Kobayashi.   

Abstract

Six children with refractory acute lymphocytic leukemia were treated with vincristine combined with diltiazem. In four of five children who took the drug as scheduled, a cytolytic effect was observed. One child showed massive cell destruction which caused hyperuricemic nephropathy. The only adverse effect was atrioventricular block in two children, which was completely reversible. Increased neurotoxicity was not observed in any child.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3859743     DOI: 10.1002/mpo.2950130408

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  8 in total

Review 1.  Genetics of multidrug resistance.

Authors:  J M Croop; P Gros; D E Housman
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

Review 2.  Multidrug resistance in pediatric oncology.

Authors:  J F Kuttesch
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 3.  Multidrug resistance in cancer chemotherapy.

Authors:  N H Patel; M L Rothenberg
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

4.  Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies.

Authors:  K S Sridhar; A Krishan; T S Samy; A Sauerteig; L L Wellham; G McPhee; R C Duncan; S Y Anac; B Ardalan; P W Benedetto
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Comparative effects of racemic verapamil vs R-verapamil on normal and leukemic progenitors.

Authors:  G Visani; M Fogli; P Tosi; E Ottaviani; B Gamberi; A Cenacchi; S Manfroi; S Tura
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

6.  Idarubicin is active on MDR cells: evaluation of DNA synthesis inhibition on P388 cell lines.

Authors:  M Petrini; L Mattii; P Valentini; A R Sabbatini; B Grassi; M Grandi
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

7.  Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers.

Authors:  F J Cowie; C R Pinkerton; M Phillips; G Dick; I Judson; P T McCarthy; R J Flanagan
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

Review 8.  Mechanisms of multidrug resistance and implications for therapy.

Authors:  T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1988-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.